Literature DB >> 3783130

Antibody-mediated early death in vivo after infection with yellow fever virus.

A D Barrett, E A Gould.   

Abstract

The phenomenon known as antibody-dependent enhancement (ADE) has been demonstrated in vitro but its significance in viral pathogenesis is uncertain even though it has been associated with dengue shock syndrome. Here we report for the first time the enhancement of virus virulence in mice using monoclonal antibodies (MAbs) prepared against yellow fever (YF) viruses. Our results show that the average survival time of mice was reduced by up to 33% (i.e. 6.7 to 4.5 days) and that ADE is both antibody dose-dependent and antibody- and virus strain-specific. A total of 12 YF viruses and 11 MAbs were examined and of these only three YF viruses (FNV, Asibi and B11) could be enhanced in vivo by only two MAbs (427 and 126). A particular combination of virus and antibody is required for ADE to take place.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783130     DOI: 10.1099/0022-1317-67-11-2539

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  22 in total

Review 1.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

2.  Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.

Authors:  Erin Mehlhop; Camilo Ansarah-Sobrinho; Syd Johnson; Michael Engle; Daved H Fremont; Theodore C Pierson; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-12-13       Impact factor: 21.023

Review 3.  Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Expert Rev Mol Med       Date:  2008-05-12       Impact factor: 5.600

4.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

5.  Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection.

Authors:  B A Lidbury; S Mahalingam
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.

Authors:  Kerrie Vaughan; Jason Greenbaum; Martin Blythe; Bjoern Peters; Alessandro Sette
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

7.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection.

Authors:  Theodore C Pierson; Qing Xu; Steevenson Nelson; Theodore Oliphant; Grant E Nybakken; Daved H Fremont; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2007-04-19       Impact factor: 21.023

10.  Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.

Authors:  Mario Lobigs; Maximilian Larena; Mohammed Alsharifi; Eva Lee; Megan Pavy
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.